The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression.
The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigue and improving physical function, independence, and quality of life.
Participants will be asked to participate in a 52-week exercise intervention consisting of a twice weekly telehealth resistance training program.
Subject age ≥ 18 years old.
Metastatic castration-sensitive prostate cancer patients who have not met criteria for disease progression (per Prostate Cancer Working Group guidelines) on current systemic therapy
Currently treated with surgical castration or medical castration with Gonadotropin-releasing hormone (GnRH) agonists/antagonists, and/or an androgen receptor pathway inhibitor (ARPI)) aka novel hormone therapy (e.g., abiraterone, enzalutamide, apalutamide, darolutamide). Must have started the current regimen at least 12 weeks prior to enrollment.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
Treatment with cytotoxic chemotherapy within 12 weeks prior to enrollment.
Estimated Glomerular Filtration Rate (eGFR) < 30 ml/min/1.73m2.
ECOG Performance Status ≥ 3
University of Utah
Lead sponsor
National Cancer Institute (NCI)
Collaborator